摘要
目的:探讨阿托伐他汀联合丹红注射液治疗椎-基底动脉硬化致脑供血不足的临床疗效。方法:选取2014年1-12月在本院接受治疗的椎-基底动脉硬化致脑供血不足患者100例,将患者随机分为观察组与对照组,每组各50例。其中对照组患者实施常规治疗,观察组患者在此基础上加以阿托伐他汀及丹红注射液进行治疗,对两组患者的治疗效果进行观察比较。结果:(1)治疗总有效率:观察组患者治疗总有效率为90.0%,对照组患者治疗总有效率为78.0%,组间比较差异有统计学意义(P<0.05)。(2)基底动脉收缩期最大流速:观察组患者基底动脉收缩期最大流速为(52.20±1.45)cm/s,对照组患者为(50.01±1.01)cm/s,组间比较差异有统计学意义(P<0.05)。(3)左、右侧椎动脉收缩期最大流速:观察组患者左侧椎动脉收缩期最大流速为(48.54±1.55)cm/s,右侧为(43.35±1.02)cm/s;对照组患者分别为(47.03±1.12)cm/s,(40.28±0.89)cm/s,组间比较差异均有统计学意义(P<0.05)。(4)不良反应比较:观察组与对照组不良反应发生率分别为4.0%与6.0%,组间比较差异无统计学意义(P>0.05)。结论:阿托伐他汀联合丹红注射液治疗椎-基底动脉硬化致脑供血不足临床效果显著,安全性较高,可有效改善病症,改善预后,促进康复。该种联合治疗方法值得在临床上广泛推广,以帮助更多患者受益。
Objective： To investigate the Atorvastatin joint Danhong Injection treatment of vertebral- basilar atherosclerosis induced clinical efficacy of cerebral insufficiency.Method： From January 2014 to December 2014 in our hospital for treatment of vertebral-basal cerebral insufficiency caused by atherosclerosis in patients with 100 cases, the patients were randomly divided into two groups and the control group, 50 cases in each group. The implementation of the control group in which patients with conventional treatment, the observation group were to Atorvastatin and Danhong Injection on the basis of treatment, the treatment effect was observed and compared two groups of patients.Result： （ 1 ） The total efficiency of the treatment： patients in the observation group total effective rate of 90.0%, the treatment of patients in the control group, the total effective rate was 78.0%, the difference between groups was statistically significant （ P〈O.05 ） . （ 2 ） The basilar artery peak systolic velocity ： the observation group were was （ 52.20 ± 1.45 ） cm/s, the control group was （ 50.01 ± 1.01 ） cm/s, the difference between groups was statistically significant （ P〈0.05 ） . （ 3 ） Left and right vertebral artery peak systolic velocity： the observation group was （ 48.54 ± 1.55 ） cm/s, the right side was （ 43.35± 1.02 ） cm/s, the control patients respectively were （ 47.03 ± 1.12 ） cm/s, （ 40.28±0.89 ） cm/s, the differences between groups were statistically significant （ P〈O.05 ） . （ 4 ） Adverse reactions ： the observation group and the control group were 4.0% and 6.0% respectively, the difference between groups was not statistically significant （ P〉0.05 ） .Conclusion： Atorvastatin joint Danhong Injection treatment of vertebral-basilar insufficiency of cerebral arteriosclerosis caused significant clinical effect, high security, can effectively improve symptoms, improve prognosis and to promote rehabilitation. This kind of combination therapy sho
出处
《中国医学创新》
CAS
2016年第26期35-39,共5页
Medical Innovation of China
关键词
阿托伐他汀
丹红注射液
椎-基底动脉硬化
脑供血不足
临床疗效
Atorvastatin
Danhong Injection
Vertebral-basilar arteriosclerosis
Cerebral insufficiency
Clinical efficacy
